Drug Trial Radar · NCT06433557
A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
22
Actual
Start
Jul 26, 2024
Primary completion
Nov 14, 2025
Study completion Nov 2027
Sponsor
- Lead sponsor
- Ascendis Pharma Growth Disorders A/SIndustry
- Sponsor type
- Industry
- First posted
- May 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.
Conditions
- Achondroplasia
Interventions
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injectionsDrug
For navepegritide, a once weekly s.c. dose of 100 μg CNP/kg. For lonapegsomatropin, a once weekly s.c. dose of lonapegsomatropin 0.30 mg hGH/kg as starting dose. Treatment duration of up to 156 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized growth velocityTime frame: Week 52
- Treatment-emergent adverse events (TEAEs).Time frame: Throughout the trial for 156 weeks
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Ascendis Pharma Investigational Site
Copenhagen, Denmark
Ascendis Pharma Investigational Site
Dublin, Ireland
Ascendis Pharma Investigational Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.